The overall goals of the Montefiore-Einstein minority-based NCORP community site are to advance the diagnosis, prevention, and management of early and advanced cancer by participating in NCORP trials as a minority/underserved community site, and contributing scientifically and administratively to the NCORP research bases. This will be accomplished by leveraging the strengths of the Montefiore Health System (MHS), including Montefiore Medical Center (MMC), which brings strengths in integrated patient care and innovative health care delivery systems in an academic medical center serving a largely minority population, and the Albert Einstein College of Medicine and Cancer Center (Einstein), which brings strength in training and education, and in baslc, translational, and clinical research through its NCI- designated cancer center. The MMC-Einstein program also brings critical leadership to the NCORP Research Bases, including ECOG-ACRIN, Alliance, and NRG, including leadership roles at the level of the group chair's office, scientific committee chair (or co-chair), and protocol chair (or co-chair). Our plans build upon our long-standing involvement in all aspects of cancer research as a main member of ECOG for 45 years and an NCI-designated cancer center for 48 years, and a strong history of minority accrual to cancer treatment trials (about 65%of all patients). MMC serves the Bronx, an urban community of 1.47 million residents, of whom 89% are minorities and 29% live below the federal poverty level. In the prior funding period we had a strong track record scientific contributions to the NCORP research bases, and met our accrual targets with exceptionally strong minority participation. In the next funding period, we will continue our strong leadership in cancer therapeutics (EA2165), expand the spectrum of our activities to include new programs in cancer imaging and screening (TMIST), cancer control/prevention (EAZ171), and cancer care delivery research (CCDR). The MMC-Einstein NCORP program is led by faculty with experience in cancer therapeutics and biomarker research (J. Sparano, MD), precision medicine and immunoncology (B. Halmos, MD), and CCDR and cancer prevention/control (B. Rapkin, PhD), and is supported by a cadre of other investigators with a broad range of expertise, some of whom benefited from NCI- funded K12 training program in clinical cancer research.

Public Health Relevance

The goal of the Montefiore-Einstein Minority/Underserved National Community Oncology Research Program (MU NCORP) is to advance the prevention, diagnosis, treatment, and management of early and advanced cancer. Our goals are to: 1) accrue at least 80 subjects to trials sponsored by the NCORP research bases (including at least 40 to therapeutic trials), 2) provide scientific and administrative leadership to the ECOG-ACRIN, NRG and Alliance research bases; 3) expand our capacity for cancer care delivery research (CCDR) to include at least 3 active CCDR protocols; 4) train and mentor young investigators in all areas of NCORP research; and 5) contribute expertise in novel methodology to address cancer health disparities, including patient engagement, trial design and outcomes measurement.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189859-07
Application #
9998867
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Montefiore Medical Center (Bronx, NY)
Department
Type
DUNS #
041581026
City
New York
State
NY
Country
United States
Zip Code
10467
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
In, Haejin; Langdon-Embry, Marisa; Gordon, Lauren et al. (2018) Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study. J Surg Res 227:246-256
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Sparano, Joseph A (2018) Prognostic gene expression assays in breast cancer: are two better than one? NPJ Breast Cancer 4:11
Rapkin, Bruce D; Weiss, Elisa; Lounsbury, David et al. (2017) Reducing Disparities in Cancer Screening and Prevention through Community-Based Participatory Research Partnerships with Local Libraries: A Comprehensive Dynamic Trial. Am J Community Psychol 60:145-159
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519

Showing the most recent 10 out of 35 publications